Details for: IGHD2 15

Gene ID: 28503

Symbol: IGHD2 15

Ensembl ID: ENSG00000211918

Description: immunoglobulin heavy diversity 2-15

Cells (max top 100)

(Marker Scores and respective Thresholds are uniquely calculated using our advanced thresholding algorithms to reveal cell-specific gene markers)

  • Cell Name: naive B cell (CL0000788)
    Fold Change: 0.02
    Marker Score: 15
  • Cell Name: double negative thymocyte (CL0002489)
    Fold Change: 0.01
    Marker Score: 8
  • Cell Name: B cell (CL0000236)
    Fold Change: 0
    Marker Score: 4

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Other Information

**Key Characteristics:** IGHD2-15 is a member of the immunoglobulin heavy chain (IgH) gene family, which encodes the heavy chains of antibodies. This gene is characterized by its unique structure and expression profile, which sets it apart from other IgH genes. Notably, IGHD2-15 is specifically expressed in cells that are in the early stages of B cell development, including naive B cells and double-negative thymocytes. This expression pattern suggests that IGHD2-15 plays a crucial role in the early stages of B cell development and maturation. **Pathways and Functions:** IGHD2-15 is involved in several key pathways that regulate B cell development and function. One of the primary functions of IGHD2-15 is to contribute to the somatic hypermutation process, which is essential for the generation of antibody diversity. This process involves the introduction of random mutations into the IgH gene, resulting in the production of diverse antibody clones. IGHD2-15 is also involved in the regulation of B cell receptor (BCR) signaling, which is critical for the activation and proliferation of B cells. Furthermore, IGHD2-15 has been implicated in the regulation of B cell differentiation and survival. The expression of IGHD2-15 is necessary for the proper differentiation of B cells into plasma cells, which are responsible for antibody production. Additionally, IGHD2-15 has been shown to play a role in the regulation of B cell apoptosis, which is essential for the elimination of self-reactive B cells. **Clinical Significance:** Dysregulation of IGHD2-15 has been implicated in several immune system disorders, including autoimmune diseases and cancer. For example, mutations in the IGHD2-15 gene have been associated with autoimmune diseases such as rheumatoid arthritis and lupus. Additionally, IGHD2-15 has been shown to play a role in the development of cancer, including B cell lymphoma and leukemia. Furthermore, IGHD2-15 has been identified as a potential target for immunotherapy in cancer treatment. The expression of IGHD2-15 on the surface of cancer cells makes it a potential target for antibody-based therapies. Additionally, the dysregulation of IGHD2-15 has been implicated in the development of immunodeficiency disorders, such as X-linked agammaglobulinemia. In conclusion, IGHD2-15 is a critical component of the adaptive immune system, playing a pivotal role in B cell development and function. Its dysregulation has been implicated in several immune system disorders, including autoimmune diseases and cancer. Further research is needed to fully understand the mechanisms by which IGHD2-15 regulates B cell development and function, and to identify potential therapeutic targets for the treatment of immune system disorders.

Database document:

This is a preview of the gene's schema. Only a few entries are kept for 'singleCellExpressions,' 'mRNAExpressions,' and other large data arrays for visualization purposes. You can zoom in with the mouse wheel for a closer view, and the text will adjust automatically if necessary. For the full schema, download it here.